TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ADHANSIA XR

METHYLPHENIDATE HYDROCHLORIDE
Approved 2019-02-27
2
Indications
--
Phase 3 Trials
7
Years on Market

Details

Status
Discontinued
First Approved
2019-02-27
Routes
ORAL
Dosage Forms
CAPSULE, EXTENDED RELEASE

Companies

Active Ingredient: METHYLPHENIDATE HYDROCHLORIDE

ADHANSIA XR Approval History

Loading approval history...

What ADHANSIA XR Treats

2 FDA approvals

Originally approved for its first indication in 2019 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ADHANSIA XR FDA Label Details

Pro

ADHANSIA XR Patents & Exclusivity

Latest Patent: Nov 2038

Patents (432 active)

US10722473 Expires Nov 19, 2038
US10111839 Expires Oct 30, 2035
US10292939 Expires Oct 30, 2035
US10512613 Expires Oct 30, 2035
US10449159 Expires Oct 30, 2035
US10500162 Expires Oct 30, 2035
US10568841 Expires Oct 30, 2035
US10292938 Expires Oct 30, 2035
US10507186 Expires Oct 30, 2035
US10512612 Expires Oct 30, 2035
+ 422 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.